Peer Exchange - Page 2

Our Peer Exchange™ program provides a multi-stakeholder perspective on important issues that providers, pharmacists, payers, and patients grapple with as they step into the world of biosimilars.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, discuss alternative payment models and their impact on patient care.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, discuss patient education on insurance coverage for biologics and other high-cost therapies, as well as the ways in which providers and patient organizations can help to increase awareness.
 
Amanda Forys, MSPH, and Christy M. Gamble, JD, DrPH, MPH, examine the exceptions process and how it affects patient access to drugs.
 
Amanda Forys, MSPH, and Christy M. Gamble, JD, DrPH, MPH, discuss payers’ decisions about whether to prefer biosimilars or their reference products, as well as patients’ perspectives on mid-year formulary changes.
Amanda Forys, MSPH, and Christy M. Gamble, JD, DrPH, MPH, discuss barriers in patient access to biosimilars.
Amanda Forys, MSPH, and Christy M. Gamble, JD, DrPH, MPH, address patient concerns about the cost of biologics and the limited savings that biosimilars currently provide in the US market.
Amanda Forys, MSPH, and Christy M. Gamble, JD, DrPH, MPH, discuss oncology patients’ awareness of biosimilars and willingness to try these therapies.
 
Molly Burich, MS; Amanda Forys, MSPH; Ha Kung Wong, JD; and Angus Worthing, MD, FACR, FACP, reflect on their discussions throughout the program and consider variables that need to be addressed in introducing biosimilars into US healthcare.
Amanda Forys, MSPH; Ha Kung Wong, JD; and Angus Worthing, MD, FACR, FACP, discuss upcoming litigation that affects biosimilars stakeholders.
Amanda Forys, MSPH; Ha Kung Wong, JD; and Angus Worthing, MD, FACR, FACP, highlight unanswered questions surrounding the Supreme Court’s ruling in Sandoz v Amgen, which reviewed procedural issues under the Biologics Price Competition and Innovation Act (BPCIA).

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.